Bicara Therapeutics Inc Sustainability Reports
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops dual-action, bifunctional therapies designed to target tumors and modulate the tumor microenvironment to treat solid tumors. Its lead program is ficerafusp alfa, which treats head and neck squamous cell carcinoma.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00Z15DGL6
1 reports from 2024 to 2024
Company Profile
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops dual-action, bifunctional therapies designed to target tumors and modulate the tumor microenvironment to treat solid tumors. Its lead program is ficerafusp alfa, which treats head and neck squamous cell carcinoma.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
